SCHEMBL31146004

SCHEMBL31146004

Cc1c(C(F)(F)C(=O)N[C@H](C)c2nc(C#N)cs2)c(=O)[nH]c2ccc(F)cc12

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PADI4 Q9UM07 1/20 0.33
▸ KDR P35968 2/20 0.33
▸ KEAP1 Q14145 1/20 0.32
▸ NFE2L2 Q16236 1/20 0.32
▸ PIK3CD O00329 2/20 0.32
▸ PIK3CG P48736 1/20 0.32
▸ CXCR2 P25025 1/20 0.32
▸ SLC2A1 P11166 1/20 0.32
▸ SLC2A3 P11169 1/20 0.32
▸ SLC2A4 P14672 1/20 0.32
▸ MPO P05164 1/20 0.32
▸ XDH P47989 1/20 0.32
▸ PGR P06401 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ CTSK P43235 1/20 0.31
▸ CTSC P53634 1/20 0.31
▸ ULK1 O75385 1/20 0.31
▸ GPR139 Q6DWJ6 1/20 0.31
▸ DRD4 P21917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31146029 1.00 PADI4 (0.33) PADI4KDRKEAP1NFE2L2PIK3CD
SCHEMBL31146062 1.00 PADI4 (0.33) PADI4KDRKEAP1NFE2L2PIK3CD
SCHEMBL31145865 0.79 KIT (0.36) PADI4PIK3CDPIK3CGCXCR2MAPK1
SCHEMBL31146144 0.79 KIT (0.36) PADI4PIK3CDPIK3CGCXCR2MAPK1
SCHEMBL31145934 0.74 ADORA2B (0.36) CXCR2CTSKCTSC
SCHEMBL31146118 0.74 ADORA2B (0.36) CXCR2CTSKCTSC
SCHEMBL31145907 0.74 ADORA2B (0.36) CXCR2CTSKCTSC
SCHEMBL31145790 0.71 ADORA2A (0.37) —
SCHEMBL31145924 0.71 ADORA2A (0.37) —
SCHEMBL31146100 0.71 KEAP1 (0.46) PADI4KEAP1NFE2L2MPOXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688748-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 — — US disclosed
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206339-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A PADI4 709/4885KDR 4224/4885KEAP1 555/4885
US-20250026740-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, COQ8A PADI4 709/4885KDR 4224/4885KEAP1 555/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 PADI4 3264/4885KDR 3362/4885KEAP1 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback